Nimbus Therapeutics to Present Update on Cbl-b Discovery Program at AACR 2022 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Nimbus Therapeutics, a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, today announced that it will present preclinical data from its Casitas B-lineage lymphoma b (Cbl-b) program at the American Association for Cancer Research (AACR) 2022 Annual Meeting, being held April 8-13, 2022 in New Orleans, LA.

Cbl-b is validated as an immuno-oncology target; the enzyme catalyzes the ubiquitination of substrate proteins to regulate multiple signaling events in a variety of cell types, including immune cells. Nimbus undertook a structure-based drug design approach to identify NTX-801, a Cbl-b inhibitor. In an in vivo PD model, NTX-801 was observed to enhance cytokine responses. In a syngeneic mouse model, NTX-801 demonstrated tumor growth inhibitory activity.

Details of the AACR presentation are as follows:

Abstract Control Number: 4649
Abstract Title: Discovery of NTX-801, a potent Cbl-b inhibitor with antitumor activity in syngeneic models
Session Title: Preclinical Immunotherapy

About Nimbus Therapeutics
Nimbus Therapeutics is a clinical-stage company that designs and develops breakthrough medicines through its powerful and comprehensive computational drug discovery engine. Nimbus’ pipeline is comprised of multiple selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and have proven difficult for drug makers to tackle. Nimbus is headquartered in Cambridge, MA. To learn more about Nimbus, please visit www.nimbustx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220328005111/en/